[Hematopoietic stem cell transplantation for malignant lymphoma].
The clinical results and indications for hematopoietic stem cell transplantation (HSCT) including malignant lymphoma(ML) will be reviewed in this paper. In aggressive non-Hodgkin's lymphoma, patients with chemosensitive relapses and induction failures are appropriate candidates for HSCT. Purged HSCT may improve outcome of patients with relapses in follicular lymphoma and mantle cell lymphoma. High dose therapy with HSCT is proposed as a potentially curative treatment for ML that is not curable with conventional chemotherapy such as induction failure, relapse, poor-risk and indolent lymphoma.
Asaoku
H
H
Fourth Department of Internal Medicine, Hiroshima Red Cross Hospital.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D016465:Bone Marrow Purging; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008223:Lymphoma / Q000628:therapy*; D008224:Lymphoma, Follicular / Q000628:therapy; D020522:Lymphoma, Mantle-Cell / Q000628:therapy; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D014182:Transplantation, Autologous